Back Hepatitis C

Hepatitis C

EASL 2014: Idenix Hepatitis C Drugs Look Promising in Early Studies

Idenix Pharmaceuticals' hepatitis C virus NS5A inhibitor samatasvir (formerly IDX179) plus Janssen's HCV protease inhibitor simeprevir (Olysio) and ribavirin produced early sustained virological response rates of about 80% in a small study presented at the 49th EASL International Liver Congress last month in London. Another study showed that the company's HCV polymerase inhibitor candidate IDX21437 looks good in preclinical studies and is a potential once-daily partner for samatasvir in interferon-free regimens.

alt

Even Moderate Alcohol Use Raises Liver Fibrosis Risk in HIV/HCV Coinfected People

People with HIV alone or hepatitis C virus alone were more likely to have advanced liver fibrosis if they drank more alcohol, but people coinfected with both HIV and HCV had a greater risk of advanced fibrosis even with moderate or "non-hazardous" drinking, according to a report in the May 15 edition of Clinical Infectious Diseases.

alt

EASL 2014: Sustained Response to Treatment Reduces Fatigue in Hepatitis C Patients

Curative treatment that eliminates hepatitis C virus (HCV) from the body can reduce central fatigue, one of the most problematic symptoms associated with chronic hepatitis C, according to research presented at the EASL Liver International Liver Congressthis month in London.

alt

EASL 2014: Sofosbuvir + Ribavirin Is Safe and Effective for HCV Recurrence after Liver Transplant

An interferon-free combination of sofosbuvir (Sovaldi) plus ribavirin taken for up to 24 weeks led to sustained virological response in 70% of liver transplant recipients with hepatitis C virus (HCV) recurrence, according to a poster presented at the 49thEASL International Liver Congress (EASL 2014) held recently in London.

alt

EASL 2014: Sofosbuvir + Ribavirin for 24 Weeks Is Highly Effective Against HCV Genotype 4

A 24-week regimen of sofosbuvir (Sovaldi) plus ribavirin cured 93% of people with hard-to-treat  hepatitis C virus (HCV) genotype 4, though treatment for only 12 weeks was not as effective, according to a poster presentation at the EASL International Liver Congress this month in London.

alt

EASL 2014: VX-135 + Daclatasvir Shows Modest Cure Rate in Phase 2 Study

Treatment with an interferon-free regimen of daclatasvir plus VX-135 for 12 weeks was safe and well-tolerated for genotype 1 chronic hepatitis C patients, but the sustained virological response rate of 83% for easier-to-treat patients did not stand up well to cure rates of 90% or higher seen with other similar combinations, according to a late-breaker poster presented at the 49thEASL International Liver Congress held recently in London.

alt

AbbVie Requests FDA Approval of Interferon-free "3D" Combo for Hepatitis C

AbbVie announced this week that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval of its "3D" regimen of direct-acting antivirals -- ABT-450/ritonavir, ombitasvir (ABT-267), and dasabuvir (ABT-333), to be used with or without ribavirin. 3D has been designated as an FDA "breakthrough therapy" and an approval decision is expected by the end of the year.

alt

Achillion Announces Start of Studies of ACH-3422 and ACH-3102 for Hepatitis C

Achillion Pharmaceuticalsannounced this week that the first participants have started receiving treatment in a Phase 1 clinical trial testing the investigational nucleotide hepatitis C virus (HCV) polymerase inhibitor ACH-3422. In addition, a recently initiated Phase 2 study is evaluating the company's next-generation NS5A inhibitor ACH-3012 in combination with Gilead Sciences' sofosbuvir (Sovaldi) for as little as 8 or even 6 weeks.

alt

EASL 2014: Kaiser Study Examines Who Receives Hepatitis C Treatment

Most people with chronic hepatitis C in the Kaiser Southern California health plan have not received treatment, often due to co-existing conditions and contraindications, but practice is evolving with the approval of more effective and better tolerated direct-acting antivirals, according to a study presented at the 49thEASL International Liver Congress this month in London.

alt